CAR-NK (AB-201)

About Artiva Biotherapeutics

Artiva Biotherapeutics is pioneering accessible NK cell therapies with a mission to treat devastating autoimmune diseases and cancers. Leveraging a proprietary manufacturing platform and a strategic partnership with GC Cell Corporation, Artiva's lead program, AlloNK®, is in multiple Phase 1/2 trials for conditions like rheumatoid arthritis and Sjögren's disease. The company differentiates itself through a scalable, allogeneic approach designed to enable outpatient treatment and broad patient access.

Therapeutic Areas